BioWorld

May 8, 2008

ImaRx Shares Spike on Sale of Urokinase to Microbix

In a deal that sent shares of ImaRx Therapeutics Inc. soaring and spurred the creation of a spin-off company, Microbix Biosystems agreed to acquire urokinase inventory and related assets from ImaRx for $17 million in cash. (BioWorld Today) Read More

Enzon to Spin Off its Biotech, Forming 2 Public Companies

Spectrum Sale of Profit Shares of Migraine Drug Nets $20M

Good Data on Riquent in Hand, La Jolla Seeks $30M Offering

ACT Biotech is Born with Pipeline, $12M

Earnings Roundup

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...